Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI

Journal of Thoracic Oncology

Volumn 10, Issue 11, 2015, Pages 1553-1559

  Hata, Akito ^a   Katakami, Nobuyuki ^a   Yoshioka, Hiroshige ^b   Kaji, Reiko ^a   Masago, Katsuhiro ^a   Fujita, Shiro ^a   Imai, Yukihiro ^a   Nishiyama, Akihiro ^b   Ishida, Tadashi ^b   Nishimura, Yoshihiro ^c   Yatabe, Yasushi ^d  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c KOBE UNIVERSITY   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acquired resistance; Epidermal growth factor receptor mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Rebiopsy; T790M

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; BRAIN TISSUE; CANCER PATIENT; CANCER TISSUE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DRUG MEGADOSE; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84945255542     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000647     Document Type: Article

References (43)

1. Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 561 566
2. Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 2129 2139
3. Paez JG, Jänne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 1497 1500
4. Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 361 947 957
5. Mitsudomi T, Morita S, Yatabe Y, West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010 11 121 128
6. Maemondo M, Inoue A, Kobayashi K, North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 362 2380 2388
7. Zhou C, Wu YL, Chen G, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011 12 735 742
8. Rosell R, Carcereny E, Gervais R, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 13 239 246
9. Sequist LV, Yang JC, Yamamoto N, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013 31 3327 3334
10. Wu YL, Zhou C, Hu CP, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014 15 213 222
11. Pao W, Miller VA, Politi KA, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 2 e73
12. Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005 352 786 792
13. Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 316 1039 1043
14. Yano S, Wang W, Li Q, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-Activating mutations. Cancer Res 2008 68 9479 9487
15. Wang W, Li Q, Yamada T, Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009 15 6630 6638
16. Sequist LV, Waltman BA, Dias-Santagata D, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011 3 75ra26
17. Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008 105 2070 2075
18. Toyooka S, Kiura K, Mitsudomi T, EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 2005 352 2136. author reply 2136
19. Inukai M, Toyooka S, Ito S, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006 66 7854 7858
20. Maheswaran S, Sequist LV, Nagrath S, Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008 359 366 377
21. Rosell R, Molina MA, Costa C, Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-Treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011 17 1160 1168
22. Su KY, Chen HY, Li KC, Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012 30 433 440
23. Chmielecki J, Foo J, Oxnard GR, Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011 3 90ra59
24. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W, New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011 17 5530 5537
25. Jackman D, Pao W, Riely GJ, Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010 28 357 360
26. Nagai Y, Miyazawa H, Huqun, Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005 65 7276 7282
27. Kosaka T, Yatabe Y, Endoh H, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006 12 5764 5769
28. Goto K, Satouchi M, Ishii G, An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012 23 2914 2919
29. Oxnard GR, Arcila ME, Sima CS, Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011 17 1616 1622
30. Hata A, Katakami N, Yoshioka H, Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-Tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. Cancer 2013 119 4325 4332
31. Janne PA, Ramalingam SS, Yang JC, Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014 32 5s. (suppl; abstr 8009)
32. Sequist LV, Soria JC, Gadgeel SM, First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014 32 5s. (suppl; abstr 8010)
33. Graziano P, de Marinis F, Gori B, EGFR-driven behavior and intrapatient T790M mutation heterogeneity of non-small-cell carcinoma with squamous histology. J Clin Oncol 2014. [Epub ahead of print]
34. Sequist LV, Waltman BA, Dias-Santagata D, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011 3 75ra26
35. Kuiper JL, Heideman DA, Thunnissen E, Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014 85 19 24
36. Hata A, Katakami N, Yoshioka H, Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases. Anticancer Res 2015 35 1025 1031
37. Jackman DM, Holmes AJ, Lindeman N, Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006 24 4517 4520
38. Hata A, Kaji R, Fujita S, Katakami N, High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol 2011 6 653 654
39. Grommes C, Oxnard GR, Kris MG, "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011 13 1364 1369
40. Hata A, Masago K, Katakami N, Imai Y, Yatabe Y, Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 2014 9 e64 e65
41. Heon S, Nishino M, Goldberg SB, Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. J Clin Oncol 2012 30
42. Asahina H, Oizumi S, Inoue A, Hokkaido Lung Cancer Clinical Study Group Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology 2010 79 423 429
43. Hata A, Katakami N, Yoshioka H, Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer 2011 74 268 273